MedTrace Logo

Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC)

NCT02702986 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-04-21

No results posted yet for this study

Summary

10 Patients with Locally Advanced Pancreatic Cancer, no further responsive to neoadjuvant treatments but with a Stage-III disease will be submitted to imILT (Immunostimulating Interstitial Laser Thermotherapy). Safety and feasibility of imILT on LAPC will be evaluated as primary objective. Secondary objectives will be QoL after imILT, study of the immune reaction after imILT, oncological analysis of patients suffering from LAPC submitted to imILT.

Conditions

Interventions

PROCEDURE

immunostimulating Interstitial Laser Thermotherapy

Through a laparotomy a laser device will be inserted into the locally advanced pancreatic cancer.

DEVICE

Laser

Sponsors & Collaborators

  • Clinical Laserthermia Systems AB

    collaborator INDUSTRY

  • Universita di Verona

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2021-10-31
Completion
2021-10-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02702986 on ClinicalTrials.gov